OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!

Dr. Dino Prato - Envita Medical Centers
  • 5.0 (2)
  • ALTERNATIVE HEALTH

OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them. For the last 25 years, Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do” We believe in personalized, data-driven medicine — not protocol-based guessing.You don’t have to fight cancer blindly. You can OutSmart it. Disclaimer:  This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico. 

  1. 1D AGO

    Cancer Patients Are Told to Eat Anything | That's Killing Them

    This video clarifies why the common advice to "eat whatever you want" during cancer treatment is misleading, emphasizing that food provides crucial signaling for your body. We explore how nutrition impacts your immune system, shapes your gut health, and plays a vital role in reducing inflammation and cancer progression. The Mediterranean diet, highlighted by research, offers significant benefits for overall health and fighting cancer, demonstrating how foods that fight cancer can be integrated into a healthy diet. 🎯 What You’ll Learn in This Episode: - Why food acts as immune and metabolic signaling - How the Mediterranean diet supports cancer outcomes - Why gut microbiome diversity matters for immunity - The difference between ancient vs modern Mediterranean diets - Why ultra-processed foods drive inflammation and disease - How to build a sustainable, lifelong anti-cancer diet - How to combine Mediterranean eating with fasting strategies - Practical food examples that support immunity and energy 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 “Food is your first immune therapy — if you choose it wisely.” Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at:  https://www.scirp.org/journal/paperinformation?paperid=132493

    13 min

  2. 2D AGO

    Squamous Cell Carcinoma of the Tongue, Head, and Neck Cancer | Dr. Dino Prato

    Dave Coulier, known for his role as Uncle Joey, shares his public battle with oral cancer. His journey included 35 rounds of radiation oncology and robotic surgeon, highlighting how outdated care can be even for those with access to top hospitals. Our aim is to help patients in their cancer treatment and maintain remission, focusing on effective strategies for head and neck cancer. 🎯 What You’ll Learn in This Episode: - What squamous cell carcinoma of the tongue is - Why head and neck radiation can affect quality of life - The potential immune links between lymphoma and other cancers - How viral infections relate to immune suppression - What deep multi-omics testing reveals - How precision immunotherapy differs from standard protocols - Why early adaptive monitoring matters - Questions to ask before starting treatment 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 “Cancer treatment should not only aim for survival — but preserve the life you’re living.” Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at:  https://www.scirp.org/journal/paperinformation?paperid=132493

    12 min

  3. 3D AGO

    Anktiva | Cancer Immune Stimulation Isn't Enough Without This?

    Anktiva is an exciting new cancer immunotherapy that helps the immune system fight and kill cancer cells. Doctors believe it could support treatment for many cancers when used in the right personalized combinations — but what is it really, and why won’t it work the same way for every patient? In this episode of Outsmart Cancer, Dr. Dino Prato breaks down the science, the hype, and the clinical reality behind Anktiva, an FDA-approved IL-15 super agonist cytokine currently indicated for invasive bladder cancer. Unlike many targeted cancer drugs that only slow disease, Anktiva is designed to activate the immune system — particularly natural killer cells and CD8 T cells — with the goal of cytotoxic tumor kill. But immune stimulation alone is not enough. Dr. Prato explains why immunotherapies like Anktiva require the right tumor information to be effective. Without exposing tumor antigens, neoantigens, and damage-associated molecular patterns (DAMPs), even powerful immune activators may produce only short-term responses. This episode explores how precision oncology integrates deep DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology to identify the right patients, pathways, and combinations. Dr. Prato outlines how direct-to-tumor strategies, micro-dosing, off-label use, and immune-supportive phytotherapeutics can transform Anktiva from a single drug into part of a coordinated immune attack. 🎯 What You’ll Learn in This Episode: - What Anktiva is and how IL-15 immunotherapy works - Why immune stimulation alone doesn’t guarantee success - The role of NK cells, CD8 T cells, and immune memory - Why tumor information must be released for immunotherapy to work - How precision testing guides on- and off-label use - Why plasma exchange may be necessary during strong immune responses - How combination strategies outperform single-agent therapy 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at:  https://www.scirp.org/journal/paperinformation?paperid=132493

    21 min

  4. 4D AGO

    Can Cancer Spread From a Biopsy? Here's What Research Says

    This video addresses a common patient fear: whether a biopsy might lead to cancer spread. We provide honest data and health education, explaining that while biopsy-related seeding is real, the information gained through procedures like lung biopsies is critical for early detection and treatment. Our aim is to empower you with health tips to make informed decisions without hype or false reassurances. 🎯 What You’ll Learn in This Episode: - Whether biopsies can really spread cancer - How rare biopsy-related seeding actually is - Why technique matters more than the needle - What the coaxial needle technique is and why it’s safer - The role of liquid biopsies and circulating tumor cells - When biopsy risk is already irrelevant due to existing spread - Why deep molecular and immune testing matters more than fear - The right questions to ask before agreeing to a biopsy 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 “Good data saves lives. Fear delays answers.” Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at:  https://www.scirp.org/journal/paperinformation?paperid=132493

    11 min

  5. 5D AGO

    The Plastic Inside Your Body Is Causing Cancer

    It is now believed that the average person carries the equivalent of a spoonful of microplastics inside their body — with emerging research suggesting significant accumulation in organs such as the brain. Yet despite growing scientific concern, microplastics remain largely ignored in conventional cancer care. In this episode of Outsmart Cancer, Dr. Dino Prato explains how microplastics function as invisible internal contaminants that drive chronic inflammation, oxidative stress, immune suppression, and genetic instability — all of which create conditions that allow cancer to grow, spread, and resist treatment. Dr. Prato explores how microplastics interfere with tumor-suppressive pathways such as p53 and NF-kappa B, disrupt hormonal signaling, and overload detoxification systems — weakening immune surveillance and reducing the effectiveness of chemotherapy, immunotherapy, and targeted treatments. Because complete avoidance is impossible in a plastic-saturated world, this episode explains why reducing total toxic burden is essential for healing. Dr. Prato outlines the only clinically applied method currently available to help remove microplastics, heavy metals, and inflammatory signaling from the bloodstream, allowing immune function to recover and cancer therapies to work more effectively. 🎯 What You’ll Learn in This Episode: How microplastics accumulate inside human tissueWhy microplastics act as toxin carriers, not passive particlesThe link between chronic inflammation, immune suppression, and cancerHow microplastics interfere with p53, apoptosis, and tumor controlWhy toxic load increases treatment resistance and side effectsWhy detoxification must accompany cancer therapyHow selective plasma exchange can reduce inflammatory burdenPractical steps to minimize ongoing microplastic exposure📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

    14 min

  6. FEB 20

    Your Immune System Is Under Attack — Here's Why Your Cancer Won't Go Away

    What if your cancer didn’t begin as bad luck in your DNA — but was fueled by hidden infections your doctors never tested for? In this episode of Outsmart Cancer, Dr. Dino Prato explains how chronic, undiagnosed infections can weaken the immune system, drive inflammation, disrupt tumor-suppressor pathways, and make cancer more aggressive and resistant to treatment. While global estimates suggest about 13% of cancers are linked to infections, Dr. Prato’s clinical experience over more than 25 years shows the number may be far higher — largely because most patients are never thoroughly tested. Viruses, bacteria, parasites, mold toxins, and tick-borne infections can persist silently in the body, suppressing immunity long before cancer develops. Dr. Prato breaks down the three primary ways infections contribute to cancer: direct oncogenic interference with tumor-suppressor genes like p53, genomic instability caused by viral integration, and chronic inflammation that fuels tumor growth and immune exhaustion. He also explains how infections disrupt mitochondrial signaling, impair natural killer cell function, and interfere with modern treatments — including immunotherapy. This episode highlights why eliminating infections and restoring immune function must be part of precision oncology. Without addressing these hidden drivers, even the most advanced cancer therapies may fail to reach their full effectiveness. 🎯 What You’ll Learn in This Episode: Why infections are an overlooked contributor to cancerHow viruses like HPV, EBV, and hepatitis affect tumor-suppressor genesThe role of chronic inflammation and immune exhaustionWhy infections increase treatment resistance and immune evasionHow mitochondrial dysfunction impacts cancer immunityWhy deep infectious disease testing is essentialHow eliminating infections can improve treatment response 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 “Cancer treatment works best when the immune system is no longer under attack.” Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

    13 min

  7. FEB 19

    Resistant Cancer Mutations Require This New Strategy

    If you’ve been told you have a KRAS mutation — or another so-called “undruggable” cancer gene — you may have been placed on a specialty inhibitor designed to slow the disease. And these drugs can be helpful. But there’s a critical truth most patients are never told: Most targeted cancer drugs are cytostatic, not cytotoxic. They slow cancer down — they don’t eliminate it. In this episode of Outsmart Cancer, Dr. Dino Prato explains why drugs targeting KRAS, BRAF, EGFR, MET, HER2, and similar pathways often create a temporary “honeymoon period.” Like unplugging a Christmas tree, the tumors dim — but once the drug stops working, the cancer lights back up. The key question becomes: What are you doing with the time these drugs buy you? Dr. Prato walks through how precision oncology uses that window to activate the immune system. By combining full DNA sequencing, RNA transcriptomics, immune spatial biology, and deep pathway mapping, doctors can identify thousands of targets — not just one mutation. This allows precision combinations, off-label strategies, phytotherapeutics, and direct-to-tumor immunotherapy delivery to expose cancer antigens, release DAMPS, and train natural killer and dendritic cells to eliminate disease system-wide. Instead of waiting for resistance, this approach turns cytostatic slowdown into cytotoxic immune control, even in patients labeled MSS or “not candidates” for standard immunotherapy. 🎯 What You’ll Learn in This Episode: • Why KRAS and similar inhibitors slow cancer but rarely eliminate it • The difference between cytostatic and cytotoxic cancer treatment • Why specialty drugs create a critical treatment window • How RNA transcriptomics reveals escape pathways beyond DNA mutations • Why immune spatial biology is essential for durable response • How direct-to-tumor delivery protects immunity and increases effectiveness • Why PD-1 inhibitors alone are rarely enough • The right questions to ask when your targeted drug stops working 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

    13 min

  8. FEB 18

    This $2 Billion Cancer Discovery Makes Radiation Look Outdated

    Something most cancer patients are never told: the radiation plan you receive is often influenced by the machine a hospital owns, not by what’s best for your cancer biology. Dr. Dino Prato breaks down the radiation wars — and introduces a disruptive technology that may change oncology entirely: ultrasound-based tumor destruction. Data shows that 40–50% of radiation therapy is palliative, meaning it’s designed to slow disease or reduce symptoms rather than eliminate cancer. The real question becomes: what are we doing during that time? Dr. Prato explains why radiation has long been an adjuvant tool, how hospital economics and reimbursement drive its overuse, and why newer technologies often struggle to gain adoption. He then introduces histotripsy and sonodynamic therapy, which use focused sound waves to “melt” tumors without radiation. This process creates a tumor lysate rich in antigens, neoantigens, and DAMPS — powerful immune signals that can be repurposed into systemic immunotherapy. Using precision oncology principles — DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided analysis — this lysate can be combined with immunotherapy, phytotherapeutic adjuvants, and nanoparticle delivery to stimulate whole-body immune response, not just local tumor control. This episode explores why ultrasound-based approaches may replace large portions of radiation oncology in the future, why adoption is slow, and how immune-centric precision care shifts cancer treatment from palliative delay to strategic immune activation. 🎯 What You’ll Learn in This Episode: • Why 40–50% of radiation therapy is palliative • How hospital ownership influences radiation decisions • The difference between radiation destruction and immune training • What histotripsy and sonodynamic therapy are • How tumor lysate becomes immunotherapy • Why ultrasound avoids many radiation side effects • How precision oncology integrates sound, data, and immunity • Why disruptive cancer technology takes years to reach patients 📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576 Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary. You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

    14 min
See All (78)

Ratings & Reviews

5
out of 5
2 Ratings

About

OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them. For the last 25 years, Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do” We believe in personalized, data-driven medicine — not protocol-based guessing.You don’t have to fight cancer blindly. You can OutSmart it. Disclaimer:  This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico. 

Information